Genoway SA
PAR:ALGEN

Watchlist Manager
Genoway SA Logo
Genoway SA
PAR:ALGEN
Watchlist
Price: 2.64 EUR 10.92%
Market Cap: 25m EUR

EV/EBIT
Enterprise Value to EBIT

12.3
Current
19
Median
7
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
12.3
=
Enterprise Value
22.4m EUR
/
EBIT
1.8m EUR
All Countries
Close
EBIT Growth EV/EBIT to Growth
FR
Genoway SA
PAR:ALGEN
Average EV/EBIT: 41.5
12.3
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 498.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.1
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16
11%
1.5
NL
argenx SE
XBRU:ARGX
60.2
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
188.6
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
36.2
2-Years Forward
EV/EBIT
54.3
3-Years Forward
EV/EBIT
15.5